Safety and efficacy of alinidine in symptom-free asthmatics
Alinidine is a new bradycardic agent which has been shown to be beneficial in the treatment of coronary heart disease. Patients with both coronary heart disease and obstructive lung disease are difficult to treat, because the use of beta-blockers in them is greatly limited by their potential to prov...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical pharmacology 1986-01, Vol.31 (4), p.427-430 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 430 |
|---|---|
| container_issue | 4 |
| container_start_page | 427 |
| container_title | European journal of clinical pharmacology |
| container_volume | 31 |
| creator | LICHEY, J HOFFMANN, M HUCKAUF, H KAMMRADT, G FRIEDRICH, T |
| description | Alinidine is a new bradycardic agent which has been shown to be beneficial in the treatment of coronary heart disease. Patients with both coronary heart disease and obstructive lung disease are difficult to treat, because the use of beta-blockers in them is greatly limited by their potential to provoke bronchospasm. Alinidine has no beta-blocking, muscarinic or quinidine-like properties. In a randomized double-blind cross-over study the heart rate reducing effect and safety of alinidine 40 mg p.o. has been examined in 12 symptom-free asthmatics. Alinidine significantly reduced mean heart rate from 81 +/- 10.5 beats/min to 65 +/- 9.7 beats/min two hours after administration. Forced expiratory volume in one second (FEV1), vital capacity (CV), airway resistance (Raw), functional residual capacity (FRC), and specific airway conductance (SGaw) were not affected. It is concluded that alinidine did not influence respiratory function in patients with bronchial hypersensitivity. |
| doi_str_mv | 10.1007/BF00613519 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00613519</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3816922</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-e6b05c7bf7c548cd6bcfbe871e35f52ad0718ef0d9fa310c645b474dfeb28eb33</originalsourceid><addsrcrecordid>eNpFkE1Lw0AURQdRaq1u3AuzcCVE38tkMgmutFgVCi7UdZiP93CkSUsmLvLvrbTU1V2cw4V7hbhEuEUAc_e4AChRaayPxBQLlWcIBR6LKYDCrKwNnIqzlL4BUNegJmKiKizrPJ-K-3fLNIzSdkESc_TWj3LN0q5iF0PsSMZOprHdDOs2455I2jR8tXaIPp2LE7arRBf7nInPxdPH_CVbvj2_zh-WmVeIQ0alA-2NY-N1UflQOs-OKoOkNOvcBjBYEUOo2SoEXxbaFaYITC6vyCk1Eze7Xt-vU-qJm00fW9uPDULzd0Dzf8BWvtrJmx_XUjio-8Vbfr3nNnm74t52PqaDVkGOWpfqF-GrYiI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Safety and efficacy of alinidine in symptom-free asthmatics</title><source>MEDLINE</source><source>Springer Nature</source><creator>LICHEY, J ; HOFFMANN, M ; HUCKAUF, H ; KAMMRADT, G ; FRIEDRICH, T</creator><creatorcontrib>LICHEY, J ; HOFFMANN, M ; HUCKAUF, H ; KAMMRADT, G ; FRIEDRICH, T</creatorcontrib><description>Alinidine is a new bradycardic agent which has been shown to be beneficial in the treatment of coronary heart disease. Patients with both coronary heart disease and obstructive lung disease are difficult to treat, because the use of beta-blockers in them is greatly limited by their potential to provoke bronchospasm. Alinidine has no beta-blocking, muscarinic or quinidine-like properties. In a randomized double-blind cross-over study the heart rate reducing effect and safety of alinidine 40 mg p.o. has been examined in 12 symptom-free asthmatics. Alinidine significantly reduced mean heart rate from 81 +/- 10.5 beats/min to 65 +/- 9.7 beats/min two hours after administration. Forced expiratory volume in one second (FEV1), vital capacity (CV), airway resistance (Raw), functional residual capacity (FRC), and specific airway conductance (SGaw) were not affected. It is concluded that alinidine did not influence respiratory function in patients with bronchial hypersensitivity.</description><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/BF00613519</identifier><identifier>PMID: 3816922</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Adult ; Asthma - physiopathology ; Biological and medical sciences ; Blood Pressure - drug effects ; Cardiovascular Agents - adverse effects ; Cardiovascular Agents - pharmacology ; Clonidine - adverse effects ; Clonidine - analogs & derivatives ; Clonidine - pharmacology ; Double-Blind Method ; Heart Rate - drug effects ; Humans ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Random Allocation ; Respiratory Function Tests ; Respiratory system</subject><ispartof>European journal of clinical pharmacology, 1986-01, Vol.31 (4), p.427-430</ispartof><rights>1987 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-e6b05c7bf7c548cd6bcfbe871e35f52ad0718ef0d9fa310c645b474dfeb28eb33</citedby><cites>FETCH-LOGICAL-c311t-e6b05c7bf7c548cd6bcfbe871e35f52ad0718ef0d9fa310c645b474dfeb28eb33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27915,27916</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8021556$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3816922$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LICHEY, J</creatorcontrib><creatorcontrib>HOFFMANN, M</creatorcontrib><creatorcontrib>HUCKAUF, H</creatorcontrib><creatorcontrib>KAMMRADT, G</creatorcontrib><creatorcontrib>FRIEDRICH, T</creatorcontrib><title>Safety and efficacy of alinidine in symptom-free asthmatics</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><description>Alinidine is a new bradycardic agent which has been shown to be beneficial in the treatment of coronary heart disease. Patients with both coronary heart disease and obstructive lung disease are difficult to treat, because the use of beta-blockers in them is greatly limited by their potential to provoke bronchospasm. Alinidine has no beta-blocking, muscarinic or quinidine-like properties. In a randomized double-blind cross-over study the heart rate reducing effect and safety of alinidine 40 mg p.o. has been examined in 12 symptom-free asthmatics. Alinidine significantly reduced mean heart rate from 81 +/- 10.5 beats/min to 65 +/- 9.7 beats/min two hours after administration. Forced expiratory volume in one second (FEV1), vital capacity (CV), airway resistance (Raw), functional residual capacity (FRC), and specific airway conductance (SGaw) were not affected. It is concluded that alinidine did not influence respiratory function in patients with bronchial hypersensitivity.</description><subject>Adult</subject><subject>Asthma - physiopathology</subject><subject>Biological and medical sciences</subject><subject>Blood Pressure - drug effects</subject><subject>Cardiovascular Agents - adverse effects</subject><subject>Cardiovascular Agents - pharmacology</subject><subject>Clonidine - adverse effects</subject><subject>Clonidine - analogs & derivatives</subject><subject>Clonidine - pharmacology</subject><subject>Double-Blind Method</subject><subject>Heart Rate - drug effects</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Random Allocation</subject><subject>Respiratory Function Tests</subject><subject>Respiratory system</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1986</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkE1Lw0AURQdRaq1u3AuzcCVE38tkMgmutFgVCi7UdZiP93CkSUsmLvLvrbTU1V2cw4V7hbhEuEUAc_e4AChRaayPxBQLlWcIBR6LKYDCrKwNnIqzlL4BUNegJmKiKizrPJ-K-3fLNIzSdkESc_TWj3LN0q5iF0PsSMZOprHdDOs2455I2jR8tXaIPp2LE7arRBf7nInPxdPH_CVbvj2_zh-WmVeIQ0alA-2NY-N1UflQOs-OKoOkNOvcBjBYEUOo2SoEXxbaFaYITC6vyCk1Eze7Xt-vU-qJm00fW9uPDULzd0Dzf8BWvtrJmx_XUjio-8Vbfr3nNnm74t52PqaDVkGOWpfqF-GrYiI</recordid><startdate>19860101</startdate><enddate>19860101</enddate><creator>LICHEY, J</creator><creator>HOFFMANN, M</creator><creator>HUCKAUF, H</creator><creator>KAMMRADT, G</creator><creator>FRIEDRICH, T</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19860101</creationdate><title>Safety and efficacy of alinidine in symptom-free asthmatics</title><author>LICHEY, J ; HOFFMANN, M ; HUCKAUF, H ; KAMMRADT, G ; FRIEDRICH, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-e6b05c7bf7c548cd6bcfbe871e35f52ad0718ef0d9fa310c645b474dfeb28eb33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1986</creationdate><topic>Adult</topic><topic>Asthma - physiopathology</topic><topic>Biological and medical sciences</topic><topic>Blood Pressure - drug effects</topic><topic>Cardiovascular Agents - adverse effects</topic><topic>Cardiovascular Agents - pharmacology</topic><topic>Clonidine - adverse effects</topic><topic>Clonidine - analogs & derivatives</topic><topic>Clonidine - pharmacology</topic><topic>Double-Blind Method</topic><topic>Heart Rate - drug effects</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Random Allocation</topic><topic>Respiratory Function Tests</topic><topic>Respiratory system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LICHEY, J</creatorcontrib><creatorcontrib>HOFFMANN, M</creatorcontrib><creatorcontrib>HUCKAUF, H</creatorcontrib><creatorcontrib>KAMMRADT, G</creatorcontrib><creatorcontrib>FRIEDRICH, T</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LICHEY, J</au><au>HOFFMANN, M</au><au>HUCKAUF, H</au><au>KAMMRADT, G</au><au>FRIEDRICH, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and efficacy of alinidine in symptom-free asthmatics</atitle><jtitle>European journal of clinical pharmacology</jtitle><addtitle>Eur J Clin Pharmacol</addtitle><date>1986-01-01</date><risdate>1986</risdate><volume>31</volume><issue>4</issue><spage>427</spage><epage>430</epage><pages>427-430</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><abstract>Alinidine is a new bradycardic agent which has been shown to be beneficial in the treatment of coronary heart disease. Patients with both coronary heart disease and obstructive lung disease are difficult to treat, because the use of beta-blockers in them is greatly limited by their potential to provoke bronchospasm. Alinidine has no beta-blocking, muscarinic or quinidine-like properties. In a randomized double-blind cross-over study the heart rate reducing effect and safety of alinidine 40 mg p.o. has been examined in 12 symptom-free asthmatics. Alinidine significantly reduced mean heart rate from 81 +/- 10.5 beats/min to 65 +/- 9.7 beats/min two hours after administration. Forced expiratory volume in one second (FEV1), vital capacity (CV), airway resistance (Raw), functional residual capacity (FRC), and specific airway conductance (SGaw) were not affected. It is concluded that alinidine did not influence respiratory function in patients with bronchial hypersensitivity.</abstract><cop>Heidelberg</cop><cop>Berlin</cop><pub>Springer</pub><pmid>3816922</pmid><doi>10.1007/BF00613519</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-6970 |
| ispartof | European journal of clinical pharmacology, 1986-01, Vol.31 (4), p.427-430 |
| issn | 0031-6970 1432-1041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1007_BF00613519 |
| source | MEDLINE; Springer Nature |
| subjects | Adult Asthma - physiopathology Biological and medical sciences Blood Pressure - drug effects Cardiovascular Agents - adverse effects Cardiovascular Agents - pharmacology Clonidine - adverse effects Clonidine - analogs & derivatives Clonidine - pharmacology Double-Blind Method Heart Rate - drug effects Humans Male Medical sciences Middle Aged Pharmacology. Drug treatments Random Allocation Respiratory Function Tests Respiratory system |
| title | Safety and efficacy of alinidine in symptom-free asthmatics |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T18%3A50%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20efficacy%20of%20alinidine%20in%20symptom-free%20asthmatics&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=LICHEY,%20J&rft.date=1986-01-01&rft.volume=31&rft.issue=4&rft.spage=427&rft.epage=430&rft.pages=427-430&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/BF00613519&rft_dat=%3Cpubmed_cross%3E3816922%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/3816922&rfr_iscdi=true |